TLR7 and neoplasm: Moreover, the combined administration of TLR7 and TLR9 agonists with PD-1 blockade in HNSCCs suppresses tumour growth and progression related to TAMs and CD8+ T cell activation and increases the ability of DCs to gain a mature phenotype and migration [100].